Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).

Full DD Report for IOVA

You must become a subscriber to view this report.


Recent News from (NASDAQ: IOVA)

Blog Exposure - RXi Pharma and Iovance Biotherapeutics Announce Research Collaboration
LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on RXi Pharma Corp. (NASDAQ: RXII ), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RXII as the Company's latest news hit the wire. On...
Source: ACCESSWIRE IA
Date: May, 15 2018 07:10
Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks
Stock Research Monitor: IOVA, JAGX, and JAZZ LONDON, UK / ACCESSWIRE / May 14, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration . WallStEquities.com shifts focus on the Biotechnology sector, which harnesses biological processes to crea...
Source: ACCESSWIRE IA
Date: May, 14 2018 07:10
Iovance Biotherapeutics' (IOVA) CEO Dr. Maria Fardis on Q1 2018 Results - Earnings Call Transcrip
Iovance Biotherapeutics, Inc. (IOVA) Q1 2018 Earnings Conference Call May 10, 2018 16:30 ET Executives Dr. Maria Fardis - President & CEO Tim Morris - CFO Analysts Mark Breidenbach - Oppenheimer Madhu Kumar - B. Riley FBR Presentation Operator Good afternoon a...
Source: SeekingAlpha
Date: May, 10 2018 22:52
Iovance Biotherapeutics misses by $0.01
Iovance Biotherapeutics (NASDAQ: IOVA ): Q1 EPS of -$0.31 misses by $0.01 . Cash, and cash equivalents of $29708M Press Release More news on: Iovance Biotherapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: May, 10 2018 16:05
Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
- Company to Host Conference Call at 4:30pm ET Today - SAN CARLOS, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported...
Source: GlobeNewswire
Date: May, 10 2018 16:01
Institutional Top Ideas Series: Orbimed Advisors
In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of...
Source: SeekingAlpha
Date: May, 04 2018 03:18
Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018
SAN CARLOS, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2018 fin...
Source: GlobeNewswire
Date: May, 03 2018 08:01
Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in May
SAN CARLOS, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investo...
Source: GlobeNewswire
Date: May, 02 2018 08:01
Report: Developing Opportunities within Enanta Pharmaceuticals, ServisFirst Bancshares, Lion Biotechnologies, Peapack-Gladstone Financial, Analogic, and Akcea Therapeutics - Future Expectations, Projections Moving into 2018
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), ServisFirst Bancshares, Inc....
Source: GlobeNewswire
Date: April, 04 2018 07:50
Biolife Solutions - Solid Close To 2017 And Off To Strong Start In 2018; Significant Opportunity Lies Ahead
Strong Q4 Close to 2017 and Off to Strong Start in 2018 Biolife Solutions ( BLFS ), a profitable company with a growing customer base that represents a who’s who of established & up-and-comers in regenerative medicine and gene therapy including Gilead/Kite Pharma ( GILD ), Blueb...
Source: SeekingAlpha
Date: March, 29 2018 12:04

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1716.6016.3517.0016.10802,846

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2552,506114,23745.9623Short
2018-05-2446,325118,51439.0882Short
2018-05-2348,556121,67539.9063Short
2018-05-2255,02797,03056.7113Short
2018-05-2147,761171,26527.8872Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IOVA.


About Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

Logo for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

Not available

 

Contact Information

 

 

Current Management

  • Manish Singh / CEO
  • Merrill A. McPeak / Interim CEO
  • Elma Hawkins / COO
  • Michael Handelman / CFO
  • Jay Venkatesan / Chairman
  • Sanford Hillsberg /
  • Ryan D. Maynard /
  • Merrill A. McPeak /

Current Share Structure

  • Market Cap: $1,359,575,446 - 05/11/2018
  • Issue and Outstanding: 89,445,753 - 02/28/2018

 


Recent Filings from (NASDAQ: IOVA)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: IOVA)

Daily Technical Chart for (NASDAQ: IOVA)


Stay tuned for daily updates and more on (NASDAQ: IOVA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: IOVA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IOVA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of IOVA and does not buy, sell, or trade any shares of IOVA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/